This undiscovered Stock is one of the most attract
Post# of 42
(Total Views: 812)
Posted On: 08/11/2017 12:59:54 PM
This undiscovered Stock is one of the most attractive that i ever recommended . Valuation is only 22 Million they have $12.6 million in Cash and they have lots of Products on the Market plus new Product launches expected within 6 months . The growing Revenue is likely to hit $16 million this year and there are only 4.3 million shares outstanding .This low float stock could hit $50 (= around $215 Million valuation) especially if they turn profitable which is expected for next Year .GL
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million
Cash: $12.6 Million
Price: $5.15
Shares Out : 4.3 Million
Presentation
http://ir.sonomapharma.com/common/download/do...ne2017.pdf
Fact Sheet
http://files.shareholder.com/downloads/OCLS/4..._Sheet.pdf
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million
Cash: $12.6 Million
Price: $5.15
Shares Out : 4.3 Million
Presentation
http://ir.sonomapharma.com/common/download/do...ne2017.pdf
Fact Sheet
http://files.shareholder.com/downloads/OCLS/4..._Sheet.pdf
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
(0)
(0)